Article from https://www.independent.co.uk/news/eu-regulator-starts-safety-review-coronavirus-drug-eu-european-medicines-agency-regulator-patients-remdesivir-b749229.html also the guardian is reporting this.
Reminder that early tests of MPL show it to be notably similar to the inhibition demonstrated for remdesivir but with a strong safety profile behind it.
^ From company ann 9th September.
PAA is currently evaluating the use of MPL for COVID in EUROPE. I hope the board is at least reaching out to the EMA with some early data and getting MPL on their radar.
EMA starts safety review of Remdesivir after causing acute kidney pain in several patients
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
16.0¢ |
Change
-0.005(3.03%) |
Mkt cap ! $77.79M | |||
| Open | High | Low | Value | Volume |
| 16.5¢ | 17.5¢ | 15.5¢ | $280.7K | 1.733M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 195397 | 16.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 16.5¢ | 43952 | 1 |
View Market Depth
| Last trade - 16.10pm 08/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |